Synergistic Suppression of Choroidal Neovascularization by Cavtratin and Aflibercept via Inhibition of the eNOS Pathway

Cavtratin combined with Aflibercept can effectively enhance anti-angiogenic efficacy and reduce inflammatory responses. Targeting the Cav-1/eNOS axis with Cavtratin provides a novel strategy to complement the limitations of anti-VEGF therapy. The synergistic effects of Cavtratin and Aflibercept suggest a promising approach to overcoming treatment resistance and improving clinical outcomes in CNV management.